Rheumatoid Arthritis - Epidemiology Forecast to 2029

November 2020 •
46 pages •
Report ID: 5744545 •
Format: PDF

Summary
Table of contents
Search Inside

Rheumatoid Arthritis - Epidemiology Forecast to 2029

Summary
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity.The condition manifests itself in multiple joints in the body (Mayo Clinic, 2019; Centers for Disease Control and Prevention, 2020).

RA is the result of an immune response in which the body’s immune system attacks its own healthy cells, especially the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response (Centers for Disease Control and Prevention, 2020). The disease can lead to premature mortality, disability, and decreased quality of life due to bone erosion and joint deformity (Brooks, 2006; Centers for Disease Control and Prevention, 2020).

Epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast.Epidemiologists used sources that confirmed RA cases based on the American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06, in order to ensure a uniform case definition across markets.

The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent (total and diagnosed) cases of RA in the 8MM, segmented by age, sex, and severity.

The following data describes epidemiology of RA. In the 8MM, Epidemiologists forecast an increase in the diagnosed incident cases of RA from 389,747 cases in 2019 to 425,455 cases in 2029, at an AGR of 0.92% over the forecast period. The diagnosed prevalent cases of RA in the 8MM will increase from 4,605,338 cases in 2019 to 5,093,229 cases in 2029, at an AGR of 1.06% over the forecast period. The total prevalent cases of RA in the 8MM will increase from 6,308,268 cases in 2019 to 6,980,823 cases in 2029, at an AGR of 1.07% over the forecast period. RA is more common in women, and the incidence and prevalence of RA typically increases with advancing age. These trends are reflected in forecast for the diagnosed incident and prevalent (total and diagnosed) cases for the 8MM.

Scope
- The Rheumatoid Arthritis (RA) Epidemiology Report provides an overview of the risk factors and global trends of IPF in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia).
- The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent cases of RA (total and diagnosed) segmented by sex and age (ages ?18 years). The prevalent cases of RA (total and diagnosed) are also segmented by severity (mild, moderate, and severe). In addition, the model corresponding to this report includes prevalent cases of RA (total and diagnosed) segmented by comorbidities (depression, cardiovascular disease, cancer, gastrointestinal ulcer, hypertension, hyperlipidemia, obesity, osteoporosis, osteoarthritis, chronic obstructive pulmonary disease, and asthma).
- The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy
The Rheumatoid Arthritis Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RA market.
- Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RA therapeutics in each of the markets covered.
- Understand magnitude of RA population by severity at diagnosis.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager